Results 101 to 110 of about 2,108,740 (316)

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

Interleukin-33 in Malignancies: Friends or Foes?

Frontiers in Immunology, 2018
The human Interleukin-33 (IL-33), a member of the IL-1 family, is the cytokine as a cell endogenous alarmin, released by damaged or necrotic barrier cells (endothelial and epithelial cells).
Jia-Xin Shen, Jia-Xin Shen, Jing Liu, Jing Liu, Guo-Jun Zhang, Guo-Jun Zhang   +5 more
doaj   +1 more source

Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye [PDF]

, 2017
Age-related macular degeneration (AMD) is the leading cause of central vision loss worldwide. Loss of retinal pigment epithelium (RPE) is a major pathological hallmark in AMD with or without pathological neovascularization.
Campbell, M, Copland, DA, Dick, AD, Doyle, SL, Gardner, PJ, Liu, J, Ozaki, E, Theodoropoulou, S, Wu, J   +8 more
core  

Implications for Interleukin-33 in solid organ transplantation [PDF]

Cytokine, 2013
Interleukin(IL)-33 is a member of the IL-1 cytokine family that has been attributed T helper (Th) type 2 immunity-promoting capacity. However, new studies indicate that IL-33 is a multifunctional protein that acts as transcriptional/signaling repressor, functions as an alarmin alerting the immune system to necrosis, as well as serves as a cytokine that
Quan, Liu, Hēth R, Turnquist
openaire   +2 more sources

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection [PDF]

, 2011
The molecular mechanisms that drive mucosal T helper type 2 (T[subscript H]2) responses against parasitic helminths and allergens remain unclear. In this study, we demonstrate in mice that TFF2 (trefoil factor 2), an epithelial cell–derived repair ...
Agrawal, Ali, Allen, Artis, Baena-Cagnani, Barron, Braman, Brancato, Brooker, Brooker, Carriere, Chang, Charles Perkins, Coyle, De’Broski R. Herbert, Dirk E. Smith, Dubeykovskaya, Evelyn A. Kurt-Jones, Fallon, Farrell, Finkelman, Finkelman, Finkelman, Follettie, Fox, Fred D. Finkelman, Gonzalo, Grivel, Guajardo, Guo, Gurjit K. Hershey, Hammad, Herbert, Herbert, Herbert, Hoshino, Hsu, Humphreys, Ian Lewkowich, Ito, James G. Fox, Jankovic, Karp, Kearley, Krista Dienger, Kuperman, Kurowska-Stolarska, Kurowska-Stolarska, Kurt-Jones, Lambrecht, Lauren Lewis, Lewkowich, Lukacs, Löhning, Marsha Wills-Karp, Marsland, Meyer, Mohrs, Nair, Neill, Nikolaidis, Nikolaidis, Oboki, Ohno, Ouyang, Paul, Paul J. Bryce, Paulsen, Pecaric-Petkovic, Phythian-Adams, Podolsky, Poulsen, Préfontaine, Pushparaj, Rani, Rank, Rankin, Reena Rani, Saenz, Schmitz, Seki, Takeuchi, Taupin, Taupin, Thim, Timothy C. Wang, Townsend, Trzpis, Umasundari Sivaprasad, van Panhuys, van Rijt, Voehringer, Wills-Karp, Zaiss, Zaph   +94 more
core   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

The Relationship between the Genetic Polymorphisms of Interleukin-33 (IL-33) and Interleukin-1 Receptor-Like 1 (IL1R1) with the Levels of Interleukin-33 in Patients with Asthma and Multiple Sclerosis

مجله دانشکده پزشکی اصفهان, 2016
Background: Recent evidence suggests that the interleukin-33/interleukin-1 receptor-like 1 (IL-33/IL1RL1) axis plays a critical role in autoimmune and inflammatory disorders; however, its mechanistic role in these diseases has not been clearly defined ...
Maryam Ahmadi, Nahid Eskandari, Fereshteh Ale-Sahebfosoul, Mansour Salehi, Ramin Ghasemi   +4 more
doaj  

Wounds that heal and wounds that don't - The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis [PDF]

, 2016
IL-33 is a member of the IL-1 family of cytokines. IL-33 is predominantly located within the nucleus of cells where it plays a role in gene regulation.
Brint, Elizabeth K., McInnes, Iain B., Millar, Neal L., O'Donnell, Charlotte   +3 more
core   +1 more source

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source